Who Buys Acyclovir from India — 879 Importers Behind a $126.0M Market
India's acyclovir import market is served by 879 active buyers who collectively imported $126.0M across 5,956 shipments. MYLAN PHARMACEUTICALS INC, (UNITED STATES) leads with a 16.3% market share, followed by MYLAN PHARMACEUTICALS INC and MYLAN PHARMACEUTICALS ULC. The top 5 buyers together control 50.7% of total import value, reflecting a moderately competitive buyer landscape.
Top Acyclovir Importers — Ranked by Import Value
MYLAN PHARMACEUTICALS INC, (UNITED STATES) is the leading acyclovir importer from India, holding a 16.3% share of the $126.0M market across 5,956 shipments from 879 buyers. The top 5 buyers — MYLAN PHARMACEUTICALS INC, (UNITED STATES), MYLAN PHARMACEUTICALS INC (UNITED STATES), MYLAN PHARMACEUTICALS ULC (CANADA), XXMBEXXPHAXXACEXXICAXX IXX (UNITED STATES), M/S. MYLAN PHARMACEUTICALS INC, (UNITED STATES) — collectively control 50.7% of total import value.
Top Acyclovir Buyers & Importers
Ranked by import value · 879 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | MYLAN PHARMACEUTICALS INC,UNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSMYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910 | $20.5M | 5 | 16.3% |
| 2 | MYLAN PHARMACEUTICALS INCUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSMYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910 | $14.9M | 5 | 11.8% |
| 3 | MYLAN PHARMACEUTICALS ULCCANADA VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSMYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910 | $11.2M | 5 | 8.9% |
| 4 | XXMBEXXPHAXXACEXXICAXX IXXUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $10.7M | 5 | 8.5% |
| 5 | M/S. MYLAN PHARMACEUTICALS INC,UNITED STATES MYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910MYLAN ACYCLOVIR 800MG TAB 100 BT PACKS 2444ACYCLOVIR TABLETS USP 400 MG (GENVIR-400 | $6.6M | 5 | 5.2% |
| 6 | SIVEM PHARMACEUTICALSUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $6.5M | 5 | 5.1% |
| 7 | EVERSANA LIFE SCIENCE SERVICESUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $4.6M | 5 | 3.7% |
| 8 | CAMBER PHARMACEUTICALS INCUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $3.0M | 5 | 2.4% |
| 9 | GENERICS & SPECIALITIES LDA ,VALE DMOZAMBIQUE ACYCLOVIR TABLETS USP 400 MG (GENVIR-400ACYCLOVIR TABLETS USP 200 MG (GENVIR-200ACYCLOVIR TABLETS USP 400 MG GENVIR-4005836X10X10 TAB | $2.3M | 5 | 1.8% |
| 10 | EUGIA US LLCUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSMYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910 | $1.8M | 5 | 1.4% |
| 11 | EUGIA US LLC,UNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSMYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910 | $1.6M | 5 | 1.2% |
| 12 | CAMBER PHARMACEUTICALS INC.UNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $1.3M | 5 | 1.1% |
| 13 | JAMP PHARMA CORPORATIONCANADA MYLAN ACYCLOVIR 400MG 100BT TAB PACKS 9910MYLAN ACYCLOVIR 800MG TAB 100 BT PACKS 2444MYLAN VALACYCLOVIR 500 MG 100 BT TAB PAC | $1.3M | 5 | 1.0% |
| 14 | NORTHSTAR HEALTHCAREUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $988.0K | 5 | 0.8% |
| 15 | NORTHSTAR HEALTHCARE SIVEM PHARMACEUTICALSUNITED STATES VALACYCLOVIR TABLETVALACYCLOVIR TABLETS USP 1 GRAM C90 4988PACKSVALACYCLOVIR 1000MG TABLETS | $704.8K | 5 | 0.6% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Acyclovir — and from which countries?
Flow of Acyclovir exports from India: each country's share and the named importers behind the numbers
Acyclovir — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $94.1M through 370 shipments. This represents a market share of 74.7% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• MYLAN PHARMACEUTICALS INC, - $20.5M (21.8% of country's total business)
• MYLAN PHARMACEUTICALS INC - $14.9M (15.8% of country's total business)
• XXMBEXXPHAXXACEXXICAXX IXX - $10.7M (11.4% of country's total business)
• M/S. MYLAN PHARMACEUTICALS INC, - $6.6M (7.0% of country's total business)
• SIVEM PHARMACEUTICALS - $6.5M (6.9% of country's total business)
• Rest of United States's importers - $34.9M (37.1% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $254.2K, indicating premium pricing strategy compared to the market average of $21.2K.
United States is a key market for Acyclovir imports, representing 74.7% of total trade value.
2Canada
Canada emerges as the second largest importing country, achieving a total trade value of $14.9M through 52 shipments. This represents a market share of 11.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• MYLAN PHARMACEUTICALS ULC - $11.2M (75.4% of country's total business)
• JAMP PHARMA CORPORATION - $1.3M (8.9% of country's total business)
• AURO PHARMA INC - $701.1K (4.7% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $285.6K, indicating premium pricing strategy compared to the market average of $21.2K.
Canada is a key market for Acyclovir imports, representing 11.8% of total trade value.
3Taiwan
Taiwan emerges as the third largest importing country, achieving a total trade value of $3.0M through 0 shipments. This represents a market share of 2.4% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Taiwan demonstrates strong market positioning with an average shipment value of $3.0M, indicating premium pricing strategy compared to the market average of $21.2K.
Taiwan is a key market for Acyclovir imports, representing 2.4% of total trade value.
4Mozambique
Mozambique emerges as the fourth largest importing country, achieving a total trade value of $2.4M through 6 shipments. This represents a market share of 1.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Mozambique has a diverse importer base, with their top importers including:
• GENERICS & SPECIALITIES LDA ,VALE D - $2.3M (97.3% of country's total business)
Key Insight: Mozambique demonstrates strong market positioning with an average shipment value of $398.7K, indicating premium pricing strategy compared to the market average of $21.2K.
Mozambique is a key market for Acyclovir imports, representing 1.9% of total trade value.
5Sweden
Sweden emerges as the fifth largest importing country, achieving a total trade value of $1.9M through 0 shipments. This represents a market share of 1.5% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Sweden demonstrates strong market positioning with an average shipment value of $1.9M, indicating premium pricing strategy compared to the market average of $21.2K.
Sweden is a key market for Acyclovir imports, representing 1.5% of total trade value.
Buyer Segment Analysis
TransData Nexus Acyclovir buyer market intelligence
1Buyer Segment Analysis
The importation of Acyclovir from India involves various buyer segments, each with distinct purchasing behaviors:
1. Distributors: Entities like MYLAN PHARMACEUTICALS INC (United States) and CAMBER PHARMACEUTICALS INC (United States) function as intermediaries, procuring large quantities of Acyclovir to supply to pharmacies, hospitals, and other healthcare providers. Their purchasing patterns are characterized by bulk orders to leverage economies of scale, ensuring a steady supply chain to meet market demand.
2. Contract Manufacturers: Companies such as EUGIA US LLC (United States) and EVERSANA LIFE SCIENCE SERVICES (United States) specialize in manufacturing pharmaceuticals on behalf of other firms. They import Acyclovir in substantial volumes to fulfill production contracts, adhering to stringent quality standards and regulatory requirements. Their procurement is project-based, aligning with contractual obligations and production schedules.
3. Re-exporters: Entities like GENERICS & SPECIALITIES LDA (Mozambique) import Acyclovir with the intent to distribute it to neighboring regions or countries. Their purchasing behavior is influenced by regional demand fluctuations and trade agreements, often involving moderate to large orders to optimize logistics and cost-effectiveness.
Each segment's procurement strategy is tailored to their operational needs, market dynamics, and regulatory environments, ensuring the efficient distribution of Acyclovir to end-users.
Country-Specific Import Regulations
TransData Nexus Acyclovir buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: Food and Drug Administration (FDA)
2. Import Registration Process for Acyclovir: Importers must ensure that Acyclovir is FDA-approved and complies with the Federal Food, Drug, and Cosmetic Act. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for approval.
3. Estimated Timeline for Registration: The FDA review process for NDAs typically takes 6 to 10 months, while ANDAs may take 10 months or more, depending on the complexity and completeness of the application.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the United States.
Canada
1. Drug Regulatory Authority: Health Canada
2. Import Registration Process for Acyclovir: Importers must obtain a Drug Identification Number (DIN) by submitting a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) to Health Canada.
3. Estimated Timeline for Registration: The review process for NDSs can take up to 300 days, while ANDSs may take approximately 180 days.
4. Import Tariff/Duty for HS 30049099: Canada generally imposes no import duties on pharmaceutical products classified under HS code 30049099.
Taiwan
1. Drug Regulatory Authority: Taiwan Food and Drug Administration (TFDA)
2. Import Registration Process for Acyclovir: Importers are required to submit a registration dossier to the TFDA, including product specifications, manufacturing details, and clinical data.
3. Estimated Timeline for Registration: The registration process typically takes 12 to 18 months, depending on the completeness of the submission and any additional information requests.
4. Import Tariff/Duty for HS 30049099: Taiwan applies a 0% import duty on pharmaceutical products under HS code 30049099.
Mozambique
1. Drug Regulatory Authority: Pharmacy Department of the Ministry of Health
2. Import Registration Process for Acyclovir: Importers must obtain marketing authorization by submitting an application that includes product information, quality control data, and evidence of GMP compliance.
3. Estimated Timeline for Registration: The registration process can take approximately 12 months, subject to the evaluation of the submitted documentation.
4. Import Tariff/Duty for HS 30049099: Mozambique imposes a standard import duty of 7.5% on pharmaceutical products under HS code 30049099.
Sweden
1. Drug Regulatory Authority: Swedish Medical Products Agency (MPA)
2. Import Registration Process for Acyclovir: Importers must submit a marketing authorization application to the MPA, including comprehensive product data and evidence of compliance with EU regulations.
3. Estimated Timeline for Registration: The process typically takes 210 days, in line with the European Medicines Agency's centralized procedure timelines.
4. Import Tariff/Duty for HS 30049099: As a member of the European Union, Sweden applies a 0% import duty on pharmaceutical products under HS code 30049099.
Demand Drivers & Market Opportunity
TransData Nexus Acyclovir buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Acyclovir across importing countries is driven by several key factors:
1. Disease Prevalence: Acyclovir is primarily used to treat herpes simplex virus (HSV) infections, including genital herpes and cold sores. The World Health Organization (WHO) reports that an estimated 3.7 billion people under age 50 (67%) globally have HSV-1 infection, and 491 million people aged 15–49 (13%) have HSV-2 infection as of 2022. This high prevalence underscores the consistent demand for antiviral treatments like Acyclovir.
2. Government Healthcare Programs and Universal Health Coverage Expansion: Many countries are enhancing their healthcare systems to provide broader access to essential medicines. For instance, Canada's universal healthcare system ensures that residents have access to necessary medications, including antivirals. Similarly, Mozambique's Ministry of Health has been working towards expanding healthcare services, increasing the accessibility of treatments for viral infections.
3. WHO Essential Medicines List Procurement and Tender-Based Purchasing: Acyclovir is listed on the WHO Model List of Essential Medicines, indicating its critical role in a basic healthcare system. This inclusion encourages countries to procure Acyclovir through national tenders and bulk purchasing agreements, ensuring availability and affordability.
With 879 buyers across 152 countries, the global market for Acyclovir reflects a substantial and sustained demand, driven by the widespread prevalence of HSV infections and the concerted efforts of governments and international organizations to provide essential antiviral treatments.
Common Questions — Acyclovir Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest acyclovir buyer importing from India?
Based on import volume and value, MYLAN PHARMACEUTICALS INC, (UNITED STATES) leads with $20.5M in imports and a 16.3% market share — the highest of any single acyclovir importer. MYLAN PHARMACEUTICALS INC (UNITED STATES) and MYLAN PHARMACEUTICALS ULC (CANADA) are the next largest buyers.
QHow many companies buy acyclovir from India?
There are 879 active acyclovir buyers importing from India, with a combined market of $126.0M across 5,956 shipments to 152 countries. The top 5 buyers hold 50.7% of total import value, while the remaining 874 buyers handle the other 49.3%.
QWhich countries import the most acyclovir from India?
The top importing countries for acyclovir from India are United States (74.7%), Canada (11.8%), Taiwan (2.4%), Mozambique (1.9%), Sweden (1.5%). These markets represent the largest demand centres for Indian pharmaceutical exports of acyclovir, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for acyclovir from India?
The average import transaction value for acyclovir from India is $21.2K, with an average unit price of $4.13 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Acyclovir buyer market intelligence
1Buyer Segment Analysis
The importation of Acyclovir from India involves various buyer segments, each with distinct purchasing behaviors:
1. Distributors: Entities like MYLAN PHARMACEUTICALS INC (United States) and CAMBER PHARMACEUTICALS INC (United States) function as intermediaries, procuring large quantities of Acyclovir to supply to pharmacies, hospitals, and other healthcare providers. Their purchasing patterns are characterized by bulk orders to leverage economies of scale, ensuring a steady supply chain to meet market demand.
2. Contract Manufacturers: Companies such as EUGIA US LLC (United States) and EVERSANA LIFE SCIENCE SERVICES (United States) specialize in manufacturing pharmaceuticals on behalf of other firms. They import Acyclovir in substantial volumes to fulfill production contracts, adhering to stringent quality standards and regulatory requirements. Their procurement is project-based, aligning with contractual obligations and production schedules.
3. Re-exporters: Entities like GENERICS & SPECIALITIES LDA (Mozambique) import Acyclovir with the intent to distribute it to neighboring regions or countries. Their purchasing behavior is influenced by regional demand fluctuations and trade agreements, often involving moderate to large orders to optimize logistics and cost-effectiveness.
Each segment's procurement strategy is tailored to their operational needs, market dynamics, and regulatory environments, ensuring the efficient distribution of Acyclovir to end-users.
Country-Specific Import Regulations
TransData Nexus Acyclovir buyer market intelligence
1Country-Specific Import Regulations
United States
1. Drug Regulatory Authority: Food and Drug Administration (FDA)
2. Import Registration Process for Acyclovir: Importers must ensure that Acyclovir is FDA-approved and complies with the Federal Food, Drug, and Cosmetic Act. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for approval.
3. Estimated Timeline for Registration: The FDA review process for NDAs typically takes 6 to 10 months, while ANDAs may take 10 months or more, depending on the complexity and completeness of the application.
4. Import Tariff/Duty for HS 30049099: Pharmaceutical products under HS code 30049099 are generally duty-free in the United States.
Canada
1. Drug Regulatory Authority: Health Canada
2. Import Registration Process for Acyclovir: Importers must obtain a Drug Identification Number (DIN) by submitting a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) to Health Canada.
3. Estimated Timeline for Registration: The review process for NDSs can take up to 300 days, while ANDSs may take approximately 180 days.
4. Import Tariff/Duty for HS 30049099: Canada generally imposes no import duties on pharmaceutical products classified under HS code 30049099.
Taiwan
1. Drug Regulatory Authority: Taiwan Food and Drug Administration (TFDA)
2. Import Registration Process for Acyclovir: Importers are required to submit a registration dossier to the TFDA, including product specifications, manufacturing details, and clinical data.
3. Estimated Timeline for Registration: The registration process typically takes 12 to 18 months, depending on the completeness of the submission and any additional information requests.
4. Import Tariff/Duty for HS 30049099: Taiwan applies a 0% import duty on pharmaceutical products under HS code 30049099.
Mozambique
1. Drug Regulatory Authority: Pharmacy Department of the Ministry of Health
2. Import Registration Process for Acyclovir: Importers must obtain marketing authorization by submitting an application that includes product information, quality control data, and evidence of GMP compliance.
3. Estimated Timeline for Registration: The registration process can take approximately 12 months, subject to the evaluation of the submitted documentation.
4. Import Tariff/Duty for HS 30049099: Mozambique imposes a standard import duty of 7.5% on pharmaceutical products under HS code 30049099.
Sweden
1. Drug Regulatory Authority: Swedish Medical Products Agency (MPA)
2. Import Registration Process for Acyclovir: Importers must submit a marketing authorization application to the MPA, including comprehensive product data and evidence of compliance with EU regulations.
3. Estimated Timeline for Registration: The process typically takes 210 days, in line with the European Medicines Agency's centralized procedure timelines.
4. Import Tariff/Duty for HS 30049099: As a member of the European Union, Sweden applies a 0% import duty on pharmaceutical products under HS code 30049099.
Demand Drivers & Market Opportunity
TransData Nexus Acyclovir buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Acyclovir across importing countries is driven by several key factors:
1. Disease Prevalence: Acyclovir is primarily used to treat herpes simplex virus (HSV) infections, including genital herpes and cold sores. The World Health Organization (WHO) reports that an estimated 3.7 billion people under age 50 (67%) globally have HSV-1 infection, and 491 million people aged 15–49 (13%) have HSV-2 infection as of 2022. This high prevalence underscores the consistent demand for antiviral treatments like Acyclovir.
2. Government Healthcare Programs and Universal Health Coverage Expansion: Many countries are enhancing their healthcare systems to provide broader access to essential medicines. For instance, Canada's universal healthcare system ensures that residents have access to necessary medications, including antivirals. Similarly, Mozambique's Ministry of Health has been working towards expanding healthcare services, increasing the accessibility of treatments for viral infections.
3. WHO Essential Medicines List Procurement and Tender-Based Purchasing: Acyclovir is listed on the WHO Model List of Essential Medicines, indicating its critical role in a basic healthcare system. This inclusion encourages countries to procure Acyclovir through national tenders and bulk purchasing agreements, ensuring availability and affordability.
With 879 buyers across 152 countries, the global market for Acyclovir reflects a substantial and sustained demand, driven by the widespread prevalence of HSV infections and the concerted efforts of governments and international organizations to provide essential antiviral treatments.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 879 global importers of Acyclovir identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 5,956 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 152 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
5,956 Verified Shipments
879 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists